Israel Biotech Fund
Daniel Pascheles is the current advisor at the Israel Biotech Fund. Daniel has over 20 years of experience in the pharmaceutical industry, having served as Vice President at both Merck & Co. USA and Aventis Pharma Inc. During their time at Aventis, they were responsible for the development and commercialization of several blockbuster drugs, including Allegra, Claritin, and Nasacort. Daniel has played a pivotal role in the growth of the Israeli biotech industry, and their work has helped to make Israel a world leader in this field.
Daniel Pascheles received their Ph. D. in Pharmacy from ETH Zürich.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Israel Biotech Fund
Israel Biotech Fund seeks high-value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies. Their key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide their portfolio companies with hands-on guidance and support.